These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 38586966)

  • 1. Effects of high-dose versus standard-dose quadrivalent influenza vaccine among patients with diabetes: A post-hoc analysis of the DANFLU-1 trial.
    Lassen MCH; Johansen ND; Modin D; Nealon J; Samson S; Dufournet M; Loiacono MM; Larsen CS; Jensen AMR; Landler NE; Claggett BL; Solomon SD; Landray MJ; Gislason GH; Køber L; Jensen JUS; Sivapalan P; Vestergaard LS; Krause TG; Biering-Sørensen T
    Diabetes Obes Metab; 2024 May; 26(5):1821-1829. PubMed ID: 38586966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of high-dose versus standard-dose quadrivalent influenza vaccine against recurrent hospitalizations and mortality in relation to influenza circulation: A post-hoc analysis of the DANFLU-1 randomized clinical trial.
    Johansen ND; Modin D; Skaarup KG; Nealon J; Samson S; Dufournet M; Loiacono MM; Harris RC; Larsen CS; Jensen AMR; Landler NE; Claggett BL; Solomon SD; Landray MJ; Gislason GH; Køber L; Jensen JUS; Sivapalan P; Vestergaard LS; Valentiner-Branth P; Krause TG; Biering-Sørensen T
    Clin Microbiol Infect; 2024 Nov; 30(11):1453-1459. PubMed ID: 38286177
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-Dose Quadrivalent Influenza Vaccine for Prevention of Cardiovascular and Respiratory Hospitalizations in Older Adults.
    Palmu AA; Pepin S; Syrjänen RK; Mari K; Mallett Moore T; Jokinen J; Nieminen H; Kilpi T; Samson SI; De Bruijn I
    Influenza Other Respir Viruses; 2024 Apr; 18(4):e13270. PubMed ID: 38569647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness for high dose quadrivalent versus the adjuvanted quadrivalent influenza vaccine in the Italian older adult population.
    Rumi F; Basile M; Cicchetti A; Alvarez FP; Azzi MV; Muzii B
    Front Public Health; 2023; 11():1200116. PubMed ID: 38026422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and effectiveness of high-dose versus standard-dose influenza vaccination for older adults: a systematic review and meta-analysis.
    Lee JKH; Lam GKL; Shin T; Kim J; Krishnan A; Greenberg DP; Chit A
    Expert Rev Vaccines; 2018 May; 17(5):435-443. PubMed ID: 29715054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of the quadrivalent high-dose influenza vaccine for prevention of cardiovascular and respiratory events in people aged 65 years and above: Rationale and design of a real-world pragmatic randomized clinical trial.
    Hollingsworth R; Palmu A; Pepin S; Dupuy M; Shrestha A; Jokinen J; Syrjänen R; Nealon J; Samson S; De Bruijn I
    Am Heart J; 2021 Jul; 237():54-61. PubMed ID: 33722585
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and effectiveness of high-dose influenza vaccine in older adults by circulating strain and antigenic match: An updated systematic review and meta-analysis.
    Lee JKH; Lam GKL; Shin T; Samson SI; Greenberg DP; Chit A
    Vaccine; 2021 Mar; 39 Suppl 1():A24-A35. PubMed ID: 33422382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of high-dose quadrivalent influenza vaccine versus standard-dose quadrivalent influenza vaccine for older people in a country with high influenza vaccination rate.
    Nham E; Seong H; Hyun H; Yoon JG; Noh JY; Cheong HJ; Kim WJ; Kim E; Choi L; Lee JM; Song JY
    Hum Vaccin Immunother; 2023 Dec; 19(3):2266233. PubMed ID: 37964587
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and immunogenicity of a high-dose quadrivalent influenza vaccine administered concomitantly with a third dose of the mRNA-1273 SARS-CoV-2 vaccine in adults aged ≥65 years: a phase 2, randomised, open-label study.
    Izikson R; Brune D; Bolduc JS; Bourron P; Fournier M; Moore TM; Pandey A; Perez L; Sater N; Shrestha A; Wague S; Samson SI
    Lancet Respir Med; 2022 Apr; 10(4):392-402. PubMed ID: 35114141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety, tolerability, and immunogenicity of influenza vaccination with a high-density microarray patch: Results from a randomized, controlled phase I clinical trial.
    Forster AH; Witham K; Depelsenaire ACI; Veitch M; Wells JW; Wheatley A; Pryor M; Lickliter JD; Francis B; Rockman S; Bodle J; Treasure P; Hickling J; Fernando GJP
    PLoS Med; 2020 Mar; 17(3):e1003024. PubMed ID: 32181756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of serious events in adults 65 years of age or older: A comparison between high-dose and standard-dose inactivated influenza vaccines.
    DiazGranados CA; Robertson CA; Talbot HK; Landolfi V; Dunning AJ; Greenberg DP
    Vaccine; 2015 Sep; 33(38):4988-93. PubMed ID: 26212007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Durability of Antibody Responses of Two Doses of High-Dose Relative to Two Doses of Standard-Dose Inactivated Influenza Vaccine in Pediatric Hematopoietic Cell Transplant Recipients: A Multi-Center Randomized Controlled Trial.
    Schuster JE; Hamdan L; Dulek DE; Kitko CL; Batarseh E; Haddadin Z; Stewart LS; Stahl A; Potter M; Rahman H; Kalams SA; Bocchini CE; Moulton EA; Coffin SE; Ardura MI; Wattier RL; Maron G; Grimley M; Paulsen G; Harrison CJ; Freedman JL; Carpenter PA; Englund JA; Munoz FM; Danziger-Isakov L; Spieker AJ; Halasa NB;
    Clin Infect Dis; 2024 Jan; 78(1):217-226. PubMed ID: 37800415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reducing Hospital Capacity Needs for Seasonal Respiratory Infections: The Case of Switching to High-Dose Influenza Vaccine for Dutch Older Adults.
    Zeevat F; Wilschut JC; Boersma C; Postma MJ
    Value Health; 2023 Apr; 26(4):461-464. PubMed ID: 36509369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose influenza vaccination and mortality among predominantly male, white, senior veterans, United States, 2012/13 to 2014/15.
    Young-Xu Y; Thornton Snider J; Mahmud SM; Russo EM; Van Aalst R; Thommes EW; Lee JK; Chit A
    Euro Surveill; 2020 May; 25(19):. PubMed ID: 32431290
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of relative effectiveness of high-dose versus standard-dose influenza vaccines using an instrumental variable method.
    Young-Xu Y; Snider JT; van Aalst R; Mahmud SM; Thommes EW; Lee JKH; Greenberg DP; Chit A
    Vaccine; 2019 Mar; 37(11):1484-1490. PubMed ID: 30745146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity and safety of high-dose quadrivalent influenza vaccine in older adults in Taiwan: A phase III, randomized, multi-center study.
    Chen JY; Hsieh SM; Hwang SJ; Liu CS; Li X; Fournier M; Yeh TY; Yin JK; Samson SI
    Vaccine; 2022 Oct; 40(45):6450-6454. PubMed ID: 36216650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized, single-blind, active-controlled phase I clinical trial to evaluate the immunogenicity and safety of GC3114 (high-dose, quadrivalent influenza vaccine) in healthy adults.
    Noh JY; Jang YS; Lee SN; Choi MJ; Yoon JG; Yu DH; Song JY; Cheong HJ; Kim WJ
    Vaccine; 2019 Aug; 37(36):5171-5176. PubMed ID: 31377075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Importance and value of adjuvanted influenza vaccine in the care of older adults from a European perspective - A systematic review of recently published literature on real-world data.
    Gärtner BC; Weinke T; Wahle K; Kwetkat A; Beier D; Schmidt KJ; Schwarz TF
    Vaccine; 2022 May; 40(22):2999-3008. PubMed ID: 35459556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Cost-Effectiveness of Vaccination of Older Adults with an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Other Available Quadrivalent Vaccines in Germany.
    Kohli MA; Maschio M; Cartier S; Mould-Quevedo J; Fricke FU
    Vaccines (Basel); 2022 Aug; 10(9):. PubMed ID: 36146464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of High-Dose Trivalent vs Standard-Dose Quadrivalent Influenza Vaccine on Mortality or Cardiopulmonary Hospitalization in Patients With High-risk Cardiovascular Disease: A Randomized Clinical Trial.
    Vardeny O; Kim K; Udell JA; Joseph J; Desai AS; Farkouh ME; Hegde SM; Hernandez AF; McGeer A; Talbot HK; Anand I; Bhatt DL; Cannon CP; DeMets D; Gaziano JM; Goodman SG; Nichol K; Tattersall MC; Temte JL; Wittes J; Yancy C; Claggett B; Chen Y; Mao L; Havighurst TC; Cooper LS; Solomon SD;
    JAMA; 2021 Jan; 325(1):39-49. PubMed ID: 33275134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.